Drug repurposing is a valuable strategy for rare diseases. Sickle cell disease (SCD) is a rare
hereditary hemolytic anemia accompanied by acute and chronic painful episodes, most
often in the context of vaso-occlusive crisis (VOC). Although progress in the knowledge of
pathophysiology of SCD have allowed the development of new therapeutic options, a large
fraction of patients still exhibits unmet therapeutic needs, with persistence of VOCs and
chronic disease progression. Here, we show that imatinib, an oral tyrosine kinase inhibitor …